Reduced CSF CART in dementia with Lewy bodies

Neuroscience Letters

Volumn 453, Issue 2, 2009, Pages 104-106

  Schultz, Kristofer ^a   Wiehager, Sara ^a   Nilsson, Karin ^b   Nielsen, Jørgen E ^c,d   Lindquist, Suzanne G ^d   Hjermind, Lena E ^c,d   Andersen, Birgitte B ^d   Wallin, Anders ^e   Nilsson, Christer ^b   Petersén, Åsa ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; Biomarker; Cerebrospinal fluid; Cocaine and amphetamine regulated transcript; Dementia

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; HYPOTHALAMUS DISEASE; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; RADIOIMMUNOASSAY; TAU PROTEINS;

EID: 61449087197     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.02.008     Document Type: Article

References (20)

1. American Psychiatric Association, American Psychiatric Association, Work Group to Revise DSM-III, Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R, American Psychiatric Association, Washington, DC, 1987, xxix, 567 p.
2. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., and Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol. Chem. Neuropathol. 26 (1995) 231-245
3. Borroni B., Agosti C., and Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. Arch. Gerontol. Geriatr. 46 (2008) 101-106
4. Brundin L., Björkqvist M., Träskman-Bendz L., and Petersén A. Cocaine and amphetamine regulated transcript (CART) in suicide attempters. Psychiatr. Res. 158 (2008) 117-122
5. Del Giudice M.E., Santoro N., Fiumani P., Dominguez G., Kuhar M.J., and Perrone L. Adolescents carrying a missense mutation in the CART gene exhibit increased anxiety and depression. Depress. Anxiety 23 (2006) 90-92
6. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., and Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5 (2006) 228-234
7. Kuhar M.J., Adams S., Dominguez G., Jaworski J., and Balkan B. CART peptides. Neuropeptides 36 (2002) 1-8
8. Lyketsos C.G., and Lee H.B. Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician. Dement. Geriatr. Cogn. Disord. 17 (2004) 55-56
9. McKeith I., Mintzer J., Aarsland D., Burn D., Chiu H., Cohen-Mansfield J., Dickson D., Dubois B., Duda J.E., Feldman H., Gauthier S., Halliday G., Lawlor B., Lippa C., Lopez O.L., Carlos Machado J., O'Brien J., Playfer J., and Reid W. International Psychogeriatric Association Expert Meeting on DLB. Dementia with Lewy bodies. Lancet Neurol. 3 (2004) 19-28
10. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C.G., Gomez-Tortosa E., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., and Yamada M. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005) 1863-1872
11. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
12. Pae C.U., Lee C., and Paik I.H. Therapeutic implication of cocaine- and amphetamine-regulated transcript (CART) in the treatment of depression. Med. Hypotheses 69 (2007) 132-135
13. Piao Y.S., Wakabayashi K., Hayashi S., Yoshimoto M., and Takahashi H. Aggregation of alpha-synuclein/NACP in the neuronal and glial cells in diffuse Lewy body disease: a survey of six patients. Clin. Neuropathol. 19 (2000) 163-169
14. Rogge G., Jones D., Hubert G.W., Lin Y., and Kuhar M.J. CART peptides: regulators of body weight, reward and other functions. Nat. Rev. Neurosci. 9 (2008) 747-758
15. Shieh K.R. Effects of the cocaine- and amphetamine-regulated transcript peptide on the turnover of central dopaminergic neurons. Neuropharmacology 44 (2003) 940-948
16. Tatsch K. Imaging of the dopaminergic system in differential diagnosis of dementia. Eur. J. Nucl. Med. Mol. Imaging 1 (2008) 51-57
17. Walker Z., Costa D.C., Walker R.W., Shaw K., Gacinovic S., Stevens T., Livingston G., Ince P., McKeith I.G., and Katona C.L. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J. Neurol. Neurosurg. Psychiatry 73 (2002) 134-140
18. Whitwell J.L., Weigand S.D., Shiung M.M., Boeve B.F., Ferman T.J., Smith G.E., Knopman D.S., Petersen R.C., Benarroch E.E., Josephs K.A., and Jack Jr. C.R. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 130 (2007) 708-719
19. World Health Organisation, International Classification of Diseases, 10th revision, New York, NY, 1992.
20. Zaccai J., McCracken C., and Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 34 (2005) 561-566